Treatment of apathy in Alzheimer's disease with transdermal rivastigmine: report of three cases

被引：1
作者：
Granero, Alessandra Lamas [1 ]
Lucchetti, Giancarlo
机构：
[1] Med Sci Sch Minas Gerais, Interdisciplinary Ctr Assistance & Res Aging, Belo Horizonte, MG, Brazil
来源：
REVISTA BRASILEIRA DE PSIQUIATRIA | 2010年 / 32卷 / 01期
关键词：
DISORDERS; DEMENTIA;
D O I：
10.1590/S1516-44462010000100019
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [41] Rivastigmine in Parkinson’s Disease DementiaProfile Report
    M. Asif A. Siddiqui
    Antona J. Wagstaff
    Drugs & Aging, 2007, 24 : 255 - 259
  • [42] Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments
    Lanctot, Krista L.
    Scherer, Roberta W.
    Li, Abby
    Vieira, Danielle
    Coulibaly, Hamadou
    Rosenberg, Paul B.
    Herrmann, Nathan
    Lerner, Alan J.
    Padala, Prasad R.
    Brawman-Mintzer, Olga
    van Dyck, Chris H.
    Porsteinsson, Anton P.
    Craft, Suzanne
    Levey, Allan
    Burke, William J.
    Mintzer, Jacobo E.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 29 (01) : 81 - 89
  • [43] The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease
    Farlow, Martin R.
    Grossberg, George
    Gauthier, Serge
    Meng, Xiangyi
    Olin, Jason T.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (10) : 2441 - 2447
  • [44] Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE)
    Gauthier, Serge
    Juby, Angela
    Dalziel, William
    Rehel, Bonita
    Schecter, Robyn
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1149 - 1160
  • [45] Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease
    Potkin, SG
    Anand, R
    Fleming, K
    Alva, G
    Keator, D
    Carreon, D
    Messina, J
    Wu, JC
    Hartman, R
    Fallon, JH
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2001, 4 (03) : 223 - 230
  • [46] Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time
    Riedel, O.
    Emmrich, A.
    Klotsche, J.
    Dodel, R.
    Foerstl, H.
    Maier, W.
    Reichmann, H.
    Wittchen, H. -U.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2012, 2 (01): : 468 - 480
  • [47] Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease
    Luis Molinuevo, Jose
    Javier Arranz, Francisco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (01) : 31 - 37
  • [48] Effects of Rivastigmine in Alzheimer's Disease Patients with and Without Hallucinations
    Cummings, Jeffrey
    Emre, Murat
    Aarsland, Dag
    Tekin, Sibel
    Dronamraju, Nalina
    Lane, Roger
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 20 (01) : 301 - 311
  • [49] Risk factors for apathy in Alzheimer's disease: A systematic review of longitudinal evidence
    Azocar, Ignacia
    Rapaport, Penny
    Burton, Alexandra
    Meisel, Georgia
    Orgeta, Vasiliki
    AGEING RESEARCH REVIEWS, 2022, 79
  • [50] Bupropion for the Treatment of Apathy in Alzheimer Disease A Randomized Clinical Trial
    Maier, Franziska
    Spottke, Annika
    Bach, Jan-Philipp
    Bartels, Claudia
    Buerger, Katharina
    Dodel, Richard
    Fellgiebel, Andreas
    Fliessbach, Klaus
    Froelich, Lutz
    Hausner, Lucrezia
    Hellmich, Martin
    Kloeppel, Stefan
    Klostermann, Arne
    Kornhuber, Johannes
    Laske, Christoph
    Peters, Oliver
    Priller, Josef
    Richter-Schmidinger, Tanja
    Schneider, Anja
    Shah-Hosseini, Kija
    Teipel, Stefan
    von Arnim, Christine A. F.
    Wiltfang, Jens
    Jessen, Frank
    JAMA NETWORK OPEN, 2020, 3 (05)
12345